Finance
Finance
HomeVCEL • NASDAQ
Vericel Corp
$37.20
Dec 11, 3:23:19 PM GMT-5 · USD · NASDAQ · Disclaimer
StockUS listed securityUS headquartered
Previous close
$37.64
Day range
$37.04 - $37.98
Year range
$29.24 - $63.00
Market cap
1.88B USD
Avg Volume
681.32K
P/E ratio
198.72
Dividend yield
-
Primary exchange
NASDAQ
Financials
Income Statement
Revenue
Net income
(USD)Sep 2025Y/Y change
Revenue
67.50M16.58%
Operating expense
46.14M4.57%
Net income
5.07M663.15%
Net profit margin
7.52582.05%
Earnings per share
0.10600.00%
EBITDA
6.39M661.37%
Effective tax rate
Total assets
Total liabilities
(USD)Sep 2025Y/Y change
Cash and short-term investments
135.38M33.07%
Total assets
453.27M16.10%
Total liabilities
131.42M-1.14%
Total equity
321.86M
Shares outstanding
50.57M
Price to book
5.91
Return on assets
1.94%
Return on capital
2.08%
Net change in cash
(USD)Sep 2025Y/Y change
Net income
5.07M663.15%
Cash from operations
22.08M116.83%
Cash from investing
-3.38M84.08%
Cash from financing
1.17M-78.89%
Net change in cash
19.87M461.03%
Free cash flow
17.89M419.74%
About
Vericel Corporation is a publicly traded American biopharmaceutical company which was known prior to October 2014 as Aastrom Bio. Aastrom Bio was formed in 1989 in Ann Arbor, Michigan. In the spring of 2014, Aastrom Bio acquired Sanofi's cell therapy and regenerative medicine business which Sanofi had acquired when purchasing Genzyme in 2011. This transformed Aastrom in several ways: it increased the employee count by 8-fold and provided a revenue stream and products to market, which it had not had before. In October 2014, the company changed its name from Aastrom Bio to Vericel and relocated its headquarters from Ann Arbor, Michigan to Cambridge, Massachusetts. Wikipedia
Founded
1989
Website
Employees
357
Discover more
You may be interested in
This list is generated from recent searches, followed securities, and other activity. Learn more

All data and information is provided “as is” for personal informational purposes only, and is not intended to be financial advice nor is it for trading purposes or investment, tax, legal, accounting or other advice. Google is not an investment adviser nor is it a financial adviser and expresses no view, recommendation or opinion with respect to any of the companies included in this list or any securities issued by those companies. Please consult your broker or financial representative to verify pricing before executing any trades. Learn more
People also search for
Search
Clear search
Close search
Google apps
Main menu